A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy

Antigen-specific cytotoxic T lymphocytes (CTLs), which eliminate target cells bearing antigenic peptides presented by surface major histocompatibility complex (MHC) class I molecules, play a key role in cancer immunotherapy. However, the majority of tumors are not immunologically rejected since they...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials research 2018, 22(3), , pp.195-201
Main Authors: Shin, Jung Min, Song, Seok Ho, Vijayakameswara Rao, N, Lee, Eun Sook, Ko, Hyewon, Park, Jae Hyung
Format: Article
Language:English
Subjects:
Antigen delivery
Antigen presentation
Autoantigens
Biomedical materials
Cancer
Cancer immunotherapy
Cancer therapies
Carboxymethyl cellulose
Carboxymethyl dextran
Care and treatment
Cervical cancer
Cervix
Chemical properties
Clinical trials
Cytotoxicity
Dextran
Immunology
Immunotherapy
Lymphocytes
Lymphocytes T
Major histocompatibility complex
Microscopy
Ovalbumin
Tumors
의공학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antigen-specific cytotoxic T lymphocytes (CTLs), which eliminate target cells bearing antigenic peptides presented by surface major histocompatibility complex (MHC) class I molecules, play a key role in cancer immunotherapy. However, the majority of tumors are not immunologically rejected since they express self-antigens which are not recognized by CTLs as foreign. To foreignize these tumors for CTL-mediated immunological rejection, it is essential to develop carriers that can effectively deliver foreign antigens to cancer cells. A polymeric conjugate, composed of a carboxymethyl dextran (CMD) as the backbone and ovalbumin (OVA) as a model foreign antigen, was prepared to investigate its potential as the antigen carrier for cancer immunotherapy. An in vitro cellular uptake study showed that the conjugate was successfully taken up by TC-1 cervical cancer cells. When CMD-OVA was systemically administered to tumor-bearing mice, the strong fluorescence signal was observed at the tumor site over the whole period of time period, suggesting high tumor targetability of the conjugate. Compared to free OVA, CMD-OVA induced significantly higher antigen presentation at the tumor site. The CMD-OVA conjugate can effectively deliver the antigen to the tumor site, implying its high potential as the antigen carrier for cancer immunotherapy.
ISSN:1226-4601
2055-7124
2055-7124
DOI:10.1186/s40824-018-0131-0